Merck And Ridgeback Biotherapeutics Provide Update On COVID-19 Treatment

Merck & Co Inc :Merck And Ridgeback Biotherapeutics Provide Update On Results From Move-Out Study Of Molnupiravir, An Investigational Oral Antiviral Medicine, In At Risk Adults With Mild-To-Moderate Covid-19.Merck & Co Inc - Nine Deaths Were Reported In Placebo Group, And One In Molnupiravir Group.Merck & Co Inc - Adverse Event Profile For Molnupiravir Remained Consistent With Profile Reported At Planned Interim Analysis.Merck - In This Study Population, Molnupiravir Reduced Risk Of Hospitalization Or Death From 9.7% In Placebo Group To 6.8% In Molnupiravir Group.Merck - Interim Analysis And Additional Analyses Support Efficacy And Overall Favorable Benefit-Risk Assessment Of Molnupiravir.Merck - Has Shared Additional Analyses With Fda, Will Be Presented To Fda'S Antimicrobial Drugs Advisory Committee On Nov. 30.